Skip to content
Dr. Grey AI

Peptide

Teduglutide (Gattex)

Teduglutide is a synthetic analog of glucagon-like peptide-2 (GLP-2) approved for the treatment of short bowel syndrome (SBS) in patients dependent on parenteral support. FDA-approved in 2012, it is the first and only GLP-2 analog available. Phase III trials demonstrated 65% response rate with 10% achieving parenteral nutrition independence. The glycine substitution at position 2 provides resistance to DPP-4 degradation.

Research notice. This page is for education and research. Peptides may not be FDA-approved for human use and may only be legally available for research. Talk to a qualified clinician before considering any peptide.

Best evidence
Grade A
Conditions studied
1
Outcomes
8
Graded outcomes
5201

Evidence by condition

  • Strong
  • Moderate
  • Limited
  • Very limited

1 condition, plus general outcomes

Short Bowel Syndrome (SBS)

Short Bowel Syndrome (SBS): outcomes studied for Teduglutide (Gattex)
GradeOutcomeEffectSizeStudiesPeopleStudies list
Parenteral Support Reduction

74% achieved 20%+ PS volume reduction at 2 years. Real-world: 36.6% reduction at 48 weeks, up to 79.3% reduction after 1 year.

Improves (the measure goes down)Large effect16 studies

Studies that measured parenteral support reduction

and 6 more in the citations list

Parenteral Nutrition Independence

10-26% of patients achieved complete parenteral nutrition independence (enteral autonomy) with teduglutide treatment.

Improves (the measure goes up)Moderate effect16 studies

Studies that measured parenteral nutrition independence

and 6 more in the citations list

Intestinal Absorption

Significant improvement in intestinal wet weight absorption capacity demonstrated in acute and chronic studies.

Improves (the measure goes up)Large effect16 studies

Studies that measured intestinal absorption

and 6 more in the citations list

Treatment Response Rate

65% response rate in Phase III clinical trials. Response defined as 20% reduction or 1-day reduction in parenteral support.

Improves (the measure goes up)Large effect15 studies

Studies that measured treatment response rate

and 5 more in the citations list

Infusion Days per Week

Significant reduction in required parenteral infusion days per week, improving quality of life and reducing catheter-related complications.

Improves (the measure goes down)Moderate effect14 studies

Studies that measured infusion days per week

and 4 more in the citations list

General

General: outcomes studied for Teduglutide (Gattex)
GradeOutcomeEffectSizeStudiesPeopleStudies list
GI Protection

41 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.

Improves (the measure goes up)Moderate effect12 studies

Studies that measured gi protection

and 2 more in the citations list

Safety/Tolerability

7 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.

Improves (the measure goes up)Small effect9 studies

Studies that measured safety/tolerability

Liver Protection

2 preclinical studies support this finding. Primarily preclinical evidence.

Improves (the measure goes up)Small effect4 studies

Studies that measured liver protection

Key findings

  • Parenteral Support ReductionShort Bowel Syndrome (SBS)Improves (the measure goes down)
  • Parenteral Nutrition IndependenceShort Bowel Syndrome (SBS)Improves (the measure goes up)
  • Intestinal AbsorptionShort Bowel Syndrome (SBS)Improves (the measure goes up)

Studies cited

37 studies from PubMed

  1. Safety of Teduglutide for Managing Patients with Short Bowel Syndrome: A Systematic Review and Meta-analysis.Pakistan journal of medical sciences, 2025 · PMID 41070320
  2. Efficacy and safety of glucagon-like peptide 2 in patients with short bowel syndrome: a systematic review and network meta-analysis.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2024 · PMID 38663565
  3. Teduglutide improves liver chemistries in short bowel syndrome-associated intestinal failure: Post hoc analysis.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition, 2024 · PMID 38491966
  4. Adult patients with short bowel syndrome treated with teduglutide: A descriptive cohort studyJPEN J Parenter Enteral Nutr, 2023 · PMID 37416984
  5. Efficacy, safety, and pharmacokinetics of teduglutide in adult Japanese patients with short bowel syndrome and intestinal failure: two phase III studies with an extension.Surgery today, 2023 · PMID 36201060
  6. Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support.Journal of pediatric gastroenterology and nutrition, 2023 · PMID 37364133
  7. [Review of real-life teduglutide experience].Nutricion hospitalaria, 2023 · PMID 37409717
  8. Teduglutide in pediatric intestinal failure: A position statement of the Italian society of pediatric gastroenterology, hepatology and nutrition (SIGENP).Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2022 · PMID 35654733
  9. Efficacy of Teduglutide for Parenteral Support Reduction in Patients with Short Bowel Syndrome: A Systematic Review and Meta-Analysis.Nutrients, 2022 · PMID 35215445
  10. Use of Teduglutide in Children With Intestinal Failure: A Systematic Review.Frontiers in nutrition, 2022 · PMID 35774551
  11. Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24-Week, Phase III Study.JPEN. Journal of parenteral and enteral nutrition, 2020 · PMID 31495952
  12. Teduglutide for the treatment of adults with intestinal failure associated with short bowel syndrome: pooled safety data from four clinical trials.Therapeutic advances in gastroenterology, 2020 · PMID 32341691
  13. Translation of Evidence Into Practice With Teduglutide in the Management of Adults With Intestinal Failure due to Short-Bowel Syndrome: A Review of Recent Literature.JPEN. Journal of parenteral and enteral nutrition, 2020 · PMID 31802516
  14. Teduglutide for the treatment of short bowel syndrome - a safety evaluationExpert Opin Drug Saf, 2018 · PMID 29848084
  15. GLP-2 analog teduglutide significantly reduces need for parenteral nutrition and stool frequency in a real-life settingTherap Adv Gastroenterol, 2018 · PMID 30364471
  16. Teduglutide effectiveness in reducing parenteral support in short bowel syndrome: a prospective studyJOP, 2018 · PMID 30008330
  17. Safety and Efficacy of Teduglutide (Gattex) in Patients With Crohn's Disease and Need for Parenteral Support Due to Short Bowel Syndrome-associated Intestinal Failure.Journal of clinical gastroenterology, 2017 · PMID 27433811
  18. Teduglutide: A Review in Short Bowel Syndrome.Drugs, 2017 · PMID 28194723
  19. Teduglutide, a glucagon-like peptide 2 analogue, in the management of patients with short bowel syndrome: an evidence-based reviewClin Drug Investig, 2016 · PMID 27095414
  20. Teduglutida: revisión de su uso en el síndrome de intestino corto.Nutricion hospitalaria, 2016 · PMID 27571675
  21. Teduglutide for Safe Reduction of Parenteral Nutrient and/or Fluid Requirements in Adults: A Systematic Review.JPEN. Journal of parenteral and enteral nutrition, 2016 · PMID 25883117
  22. Teduglutide for the treatment of short bowel syndromeExpert Opin Biol Ther, 2015 · PMID 26485142
  23. Gut hormones in the treatment of short-bowel syndrome and intestinal failure.Current opinion in endocrinology, diabetes, and obesity, 2015 · PMID 25485516
  24. Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in short bowel syndromeJ Parenter Enteral Nutr, 2014 · PMID 24399211
  25. New approaches to the treatments of short bowel syndrome-associated intestinal failure.Current opinion in gastroenterology, 2014 · PMID 24406477
  26. Intestinal adaptation following resection.JPEN. Journal of parenteral and enteral nutrition, 2014 · PMID 24586019
  27. Pharmacologic options for intestinal rehabilitation in patients with short bowel syndrome.JPEN. Journal of parenteral and enteral nutrition, 2014 · PMID 24615689
  28. Efficacy and safety of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failureClin Gastroenterol Hepatol, 2013 · PMID 23973176
  29. Teduglutide enhances structural adaptation of the small intestinal mucosa in patients with short bowel syndrome.Journal of clinical gastroenterology, 2013 · PMID 23426461
  30. Teduglutide: a review of its use in the treatment of patients with short bowel syndrome.Drugs, 2013 · PMID 23729002
  31. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failureGastroenterology, 2012 · PMID 22464623
  32. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure.Gastroenterology, 2012 · PMID 22982184
  33. Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndromeGastroenterol Hepatol (N Y), 2010 · PMID 21154171
  34. Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndromeCPT Pharmacometrics Syst Pharmacol, 2009 · PMID 19847163
  35. Teduglutide in intestinal adaptation and repair: light at the end of the tunnel.Expert opinion on investigational drugs, 2008 · PMID 18491995
  36. Teduglutide for the treatment of short bowel syndromeLancet, 2005 · PMID 16705029
  37. Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage.Cell proliferation, 2004 · PMID 15548172